These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 29239844

  • 1. Selected High-Risk Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy for Adjuvant Chemotherapy: A Multi-Institutional Retrospective Study.
    Ikeda M, Matsumoto K, Hirayama T, Koguchi D, Murakami Y, Matsuda D, Okuno N, Utsunomiya T, Taoka Y, Irie A, Iwamura M.
    Clin Genitourin Cancer; 2018 Jun; 16(3):e669-e675. PubMed ID: 29239844
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study.
    Nakagawa T, Komemushi Y, Kawai T, Otsuka M, Miyakawa J, Uemura Y, Kanatani A, Taguchi S, Naito A, Suzuki M, Nishimatsu H, Hirano Y, Tanaka Y, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y.
    World J Urol; 2017 Oct; 35(10):1569-1575. PubMed ID: 28397000
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma.
    Seisen T, Krasnow RE, Bellmunt J, Rouprêt M, Leow JJ, Lipsitz SR, Vetterlein MW, Preston MA, Hanna N, Kibel AS, Sun M, Choueiri TK, Trinh QD, Chang SL.
    J Clin Oncol; 2017 Mar 10; 35(8):852-860. PubMed ID: 28045620
    [Abstract] [Full Text] [Related]

  • 4. Role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma and the prognostic significance of C-reactive protein: A multi-institutional, retrospective study.
    Fujita K, Inamoto T, Yamamoto Y, Tanigawa G, Nakayama M, Mori N, Tsujihata M, Azuma H, Nonomura N, Uemura M.
    Int J Urol; 2015 Nov 10; 22(11):1006-12. PubMed ID: 26153093
    [Abstract] [Full Text] [Related]

  • 5. Impact of the ASA Physical Status Score on Adjuvant Chemotherapy Eligibility and Survival of Upper Tract Urothelial Carcinoma Patients: a Multicenter Study.
    Kang HW, Seo SP, Kim WT, Kim YJ, Yun SJ, Lee SC, Choi YD, Ha YS, Kim TH, Kwon TG, Byun SS, Jeh SU, Kim WJ.
    J Korean Med Sci; 2017 Feb 10; 32(2):335-342. PubMed ID: 28049247
    [Abstract] [Full Text] [Related]

  • 6. The efficacy and timing of adjuvant chemotherapy in upper tract urothelial carcinoma.
    Li H, Zhou J, Chen R, Zhu J, Wang J, Wen R.
    Urol Oncol; 2023 Aug 10; 41(8):356.e1-356.e9. PubMed ID: 37331821
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome.
    Yafi FA, Tanguay S, Rendon R, Jacobsen N, Fairey A, Izawa J, Kapoor A, Black P, Lacombe L, Chin J, So A, Lattouf JB, Bell D, Fradet Y, Saad F, Matsumoto E, Drachenberg D, Cagiannos I, Kassouf W.
    Urol Oncol; 2014 Jan 10; 32(1):31.e17-24. PubMed ID: 23428535
    [Abstract] [Full Text] [Related]

  • 9. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
    Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, Lotan Y, Raman JD, Kassouf W, Zigeuner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Bolenz C, Roscigno M, Koppie TM, Ng CK, Fritsche HM, Matsumoto K, Walton TJ, Ehdaie B, Tritschler S, Fajkovic H, Martínez-Salamanca JI, Pycha A, Langner C, Ficarra V, Patard JJ, Montorsi F, Wood CG, Karakiewicz PI, Margulis V.
    Eur Urol; 2012 Apr 10; 61(4):818-25. PubMed ID: 22284969
    [Abstract] [Full Text] [Related]

  • 10. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma.
    Fritsche HM, Novara G, Burger M, Gupta A, Matsumoto K, Kassouf W, Sircar K, Zattoni F, Walton T, Tritschler S, Baba S, Bastian PJ, Martínez-Salamanca JI, Seitz C, Otto W, Wieland WF, Karakiewicz PI, Ficarra V, Hartmann A, Shariat SF.
    Urol Oncol; 2012 Sep 10; 30(5):666-72. PubMed ID: 20933445
    [Abstract] [Full Text] [Related]

  • 11. Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy.
    Lee KS, Kim KH, Yoon YE, Choi KH, Yang SC, Han WK.
    Korean J Urol; 2015 Jan 10; 56(1):41-7. PubMed ID: 25598935
    [Abstract] [Full Text] [Related]

  • 12. Prognostic Value of Lymphovascular Invasion in Node-Negative Upper Urinary Tract Urothelial Carcinoma Patients Undergoing Radical Nephroureterectomy.
    Liu W, Zhou Z, Dong D, Sun L, Zhang G.
    Yonsei Med J; 2019 Feb 10; 60(2):174-181. PubMed ID: 30666839
    [Abstract] [Full Text] [Related]

  • 13. Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study.
    Shigeta K, Matsumoto K, Ogihara K, Murakami T, Anno T, Umeda K, Izawa M, Baba Y, Sanjo T, Shojo K, Tanaka N, Takeda T, Morita S, Kosaka T, Mizuno R, Arita Y, Akita H, Jinzaki M, Kikuchi E, Oya M.
    Urol Oncol; 2022 Mar 10; 40(3):105.e19-105.e26. PubMed ID: 34454822
    [Abstract] [Full Text] [Related]

  • 14. Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis.
    Fujita K, Taneishi K, Inamoto T, Ishizuya Y, Takada S, Tsujihata M, Tanigawa G, Minato N, Nakazawa S, Takada T, Iwanishi T, Uemura M, Okuno Y, Azuma H, Norio N.
    BMC Urol; 2017 Dec 01; 17(1):110. PubMed ID: 29195499
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impact of adjuvant chemotherapy on oncologic outcomes following radical nephroureterectomy for patients with pT3NanyM0 upper tract urothelial carcinoma: A retrospective cohort study.
    Song W, Jeong JY, Jeon HG, Seo SI, Jeon SS, Choi HY, Lee HM, Sung HH.
    Int J Surg; 2019 Jun 01; 66():12-17. PubMed ID: 31018160
    [Abstract] [Full Text] [Related]

  • 17. Impact of histologic variants on the oncological outcomes of patients with upper urinary tract cancers treated with radical surgery: a multi-institutional retrospective study.
    Murakami Y, Matsumoto K, Ikeda M, Hirayama T, Utsunomiya T, Koguchi D, Matsuda D, Okuno N, Taoka Y, Irie A, Iwamura M.
    Int J Clin Oncol; 2019 Nov 01; 24(11):1412-1418. PubMed ID: 31197556
    [Abstract] [Full Text] [Related]

  • 18. High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy.
    Raman JD, Lin YK, Kaag M, Atkinson T, Crispen P, Wille M, Smith N, Hockenberry M, Guzzo T, Peyronnet B, Bensalah K, Simhan J, Kutikov A, Cha E, Herman M, Scherr D, Shariat SF, Boorjian SA.
    Urol Oncol; 2014 Jan 01; 32(1):47.e9-14. PubMed ID: 24140248
    [Abstract] [Full Text] [Related]

  • 19. Adjuvant chemotherapy after radical nephroureterectomy improves the survival outcome of high-risk upper tract urothelial carcinoma patients with cardiovascular comorbidity.
    Luo Y, Feng B, Wei D, Han Y, Li M, Zhao J, Lin Y, Hou Z, Jiang Y.
    Sci Rep; 2020 Oct 19; 10(1):17674. PubMed ID: 33077839
    [Abstract] [Full Text] [Related]

  • 20. Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy.
    Vartolomei MD, Mathieu R, Margulis V, Karam JA, Rouprêt M, Lucca I, Mbeutcha A, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Rioux-Leclercq N, Haitel A, Bensalah K, Rink M, Briganti A, Xylinas E, Shariat SF.
    World J Urol; 2017 Jan 19; 35(1):121-130. PubMed ID: 27209168
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.